American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Health-related quality of life and symptoms among patients with relapsed or refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice: Results from a randomized phase 3 trial
    Meeting Abstract

    Sanchorawala, V.; Wechalekar, A. D.; Kim, K.; Schönland, S.; Landau, H. J.; Fiona, K.; Suzuki, K.; Dispenzieri, A.; Merlini, G.; Comenzo, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • High rates of remission with the initial treatment of oral azacitidine plus CHOP for peripheral T-cell lymphoma (PTCL): Clinical outcomes and biomarker analysis of a multi-center phase II study
    Meeting Abstract

    Ruan, J.; Moskowitz, A. J.; Mehta-Shah, N.; Sokol, L.; Chen, Z.; Rahim, R.; Song, W.; Kotlov, N.; Nos, G.; Maksimov, V.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Efficacy comparison of tisagenlecleucel versus standard of care in patients with relapsed or refractory follicular lymphoma
    Meeting Abstract

    Salles, G.; Schuster, S. J.; Dreyling, M. H.; Fischer, L.; Kuruvilla, J.; Patten, P. E. M.; Von Tresckow, B.; Smith, S. M.; Ubieto, A. I. J.; Davis, K. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 1a/b dose escalation study of the mutation agnostic BTK/FLT3 inhibitor luxeptinib (CG-806) in patients with relapsed or refractory B-cell malignancies
    Meeting Abstract

    Samaniego, F.; Burke, J. M.; Mahadevan, D.; Cherry, M.; Sadiq, A. A.; Koontz, M. Z.; Villasboas, J. C.; Reid, E.; Cull, E.; Priego, V.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Monoclonal gammopathy of undetermined significance and COVID-19: Results from the population-based Iceland screens treats or prevents multiple myeloma study (iStopMM)
    Meeting Abstract

    Rögnvaldsson, S; Eythorsson, E.; Thorsteinsdottir, S.; Vidarsson, B.; Onudarson, P. T.; Agnarsson, B. A.; Sigurdardottir, M.; Horsteinsdottir, I.; Olafsson, I.; Runolfsdottir, H. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Single-cell multi-omics reveals that pegylated interferon-alfa treatment differentially redirects mutated and wildtype hematopoietic cell differentiation trajectories in CALR-mutated essential thrombocythemia (ET) patients
    Meeting Abstract

    Rosenberg, S.; Kubas-Meyer, A.; Parghi, N.; Omans, N. D.; Dusai, N.; Chamely, P.; Mimitou, E.; Dueck, A. C.; Kosiorek, H. E.; Weinberg, R. S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • "Building a more inclusive blood system in Canada": A mixed-methods evaluation of a workshop to guide medical students to develop as health advocates through advancing health equity in blood product donation for gay, bisexual, and queer men
    Meeting Abstract

    Rosenfeld, A.; Baribeau, O.; Berscheid, K.; Chan, S. W. S.; Farrokhi, K.; Herman, D.; Lee, A.; Segall, R.; Singh, N.; Wroot, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The incidence and impact of clostridioides difficile infection (CDI) on outcomes after allogeneic hematopoietic cell transplant (alloHCT) - a CIBMTR study
    Meeting Abstract

    Ramanathan, M.; Savani, B. B.; He, N. Y.; Kim, S.; Chen, M.; Chemaly, R.; Dandoy, C. E.; Perales, M. A.; Riches, M. L.; Ustun, C.
    Blood (2021)

    Fulltext@MSK | Save
  • A multicenter analysis of outcomes, toxicities, and patterns of use with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas
    Meeting Abstract

    Riedell, P. A.; Brower, J.; Nastoupil, L.; Perales, M. A.; Maziarz, R. T.; McGuirk, J. P.; Bachanova, V.; Hwang, W. T.; Schuster, S. J.; Bishop, M. R.; more...
    Blood (2021)

    Fulltext@MSK | Save